文献速递造血干细胞移植与细胞治疗白血病

移植后环磷酰胺与抗胸腺细胞球蛋白在HLA错配无关供者移植中的比较

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
PubMed 文献 · Blood · 2019-07-03

该研究基于欧洲血液与骨髓移植学会急性白血病工作组注册数据,采用配对分析比较9/10 HLA错配无关供者移植中移植后环磷酰胺(PTCY)与抗胸腺细胞球蛋白(ATG)的结局。亚组分析证实PTCY优于ATG。

要点

  • 在9/10 MMUD移植中,PTCY较ATG显著降低严重急性GVHD发生率。
  • PTCY组无白血病生存和GVHD/无复发生存均高于ATG组。
  • 外周血干细胞、完全缓解或相同免疫抑制剂的亚组分析中PTCY优势仍被证实。

核心结论

  • 在9/10 HLA错配无关供者移植中,PTCY是有效的抗GVHD预防方案,可能提供更好的长期疾病控制结局。
  • 这些结果需在大型前瞻性随机试验中确认。

研究设计与样本

  • 基于欧洲血液与骨髓移植学会急性白血病工作组注册数据的配对分析。

主要发现

  • PTCY组较ATG组严重急性GVHD发生率显著更低。
  • PTCY组无白血病生存高于ATG组。
  • PTCY组GVHD/无复发生存(GRFS)高于ATG组。
  • 亚组分析(外周血干细胞、完全缓解、相同免疫抑制劑)中PTCY优于ATG被证实。

临床怎么用

  • 在9/10 MMUD移植中,PTCY可作为抗GVHD预防的有效选择。
  • PTCY可能带来更好的长期疾病控制结局。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of anti-thymocyte globulin (ATG) has represented the standard of care in graft-versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated donor (MMUD) transplant. The safety and feasibility of posttransplant cyclophosphamide (PTCY) in this setting have been reported recently, but no study has compared the outcomes of PTCY vs ATG in 9/10 MMUD transplants. Using the registry data of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we performed a matched-pair analysis comparing those 2 strategies in a 9/10 MMUD setting. Ninety-three patients receiving PTCY were matched with 179 patients receiving ATG. A significantly lower incidence of severe acute GVHD was observed with PTCY compared with ATG. Recipients of the former also showed higher leukemia-free survival and GVHD/relapse-free survival (GRFS). When performing a subgroup analysis including patients receiving peripheral blood stem cells, being in complete remission, or receiving the same associated immunosuppressive agents, superiority of PTCY over ATG was confirmed. Similar to the haploidentical setting, use of PTCY is an effective anti-GVHD prophylaxis in the 9/10 MMUD transplant. Use of PTCY may also provide better outcomes in long-term disease control. These results need confirmation in large prospective randomized trials.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Battipaglia G, Labopin M, Kröger N, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019. PMID: 31270102. doi:10.1182/blood.2019000487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。